Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib in MET-high inoperable hepatocellular carcinoma
NCT01755767Phase 3
Key facts
- Status
- Completed
- Start
- Dec 2012
- Primary completion
- Mar 2017
- Countries
- 16
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Modality
- Small Molecules
- Drugs
- tivantinib
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 3, randomised, double-blind trial of tivantinib in hepatocellular carcinoma (HCC), sponsored by Daiichi Sankyo Co., Ltd. Started Dec 2012; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with MET-high inoperable HCC who failed one prior sorafenib-containing systemic therapy, with Child-Pugh A status and no significant cardiac history.
04
Results
Not all primary endpoints met
05
Registry description
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
Beyond the preview
Go deeper on NCT01755767.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01755767.